575 completed, 205 terminated, 191 recruiting, 98 unknown. 1251 Phase 1, 412 Phase 2.
Follow Adnexal Diseases: new trials by email Literature Review of Adnexal Diseases trials Research Report on Adnexal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-11-13 | 2026-10-13 |
| Oral GDC-0077 in Premature Ovarian Insufficiency GDC-0077 - Primary Ovarian Insufficiency | Phase 1 | Not yet recruiting | Women's Hospital School Of Medicine Zhejiang University | 12 | 2026-10-30 | 2026-10-29 |
| Phase 1 Study of VT-101 in Advanced Ovarian Cancer VT-101 - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 1 | Not yet recruiting | Michael J. Goodheart | 22 | 2026-10-23 | 2026-10-29 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. YF550 - Solid Tumor (Phase I), Ovarian Cancer | Phase 1 | Not yet recruiting | InventisBio Yiqi Beijing Limited | 204 | 2026-10-01 | 2026-10-26 |
| A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. TJ102 - Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Phrontline Biopharma | 150 | 2026-09-29 | 2026-10-21 |
| Evaluation of XYA02 in Patients With Advanced Solid Tumors XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | XYone Therapeutics, Inc | 190 | 2026-09-17 | 2026-09-25 |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors ABBV-253 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AbbVie | 130 | 2026-09-14 | 2026-10-16 |
| A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery Low Dose, middle dose, high dose - Ovarian Cancer, mRNA Vaccine | Phase 1 | Recruiting | West China Hospital | 9 | 2026-09-10 | 2026-09-09 |
| A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery Low Dose NeoOVIV, Medium dose NeoOVIV, High dose NeoOVIV - Ovarian Cancer, mRNA Vaccine | Phase 1 | Recruiting | West China Hospital | 9 | 2026-09-10 | 2026-09-09 |
| A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of Chicago | 24 | 2026-09-09 | 2026-10-13 |
| A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors TS-104 - NSCLC (Non-small Cell Lung Cancer), HNSCC | Phase 1 | Recruiting | TwoStep Therapeutics, Inc. | 74 | 2026-09-02 | 2026-09-30 |
| Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors 111In-TJD-31 Injection - Solid Tumors, Carcinoma | Phase 1 | Not yet recruiting | Yong He | 8 | 2026-09-01 | 2026-09-11 |
| Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer CryptiVax-1001 - Ovarian Cancer, HGSOC | Phase 1 | Recruiting | Epitopea Ltd | 50 | 2026-09-01 | 2026-10-16 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain Custom-formulated, high-CBD study product, Placebo - Endometriosis, Adenomyosis | Phase 1 / Phase 2 | Recruiting | Staci Gruber, Ph.D. | 60 | 2026-09-01 | 2026-07-27 |
| Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer (Arginaid®) Oral Arginine, (R-Gene® 10) IV Arginine, Pembrolizumab - Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Rebecca Arend | 24 | 2026-09-01 | 2026-10-15 |
| GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion - Platinum-resistant Ovarian Cancer | Phase 1 | Recruiting | Roswell Park Cancer Institute | 33 | 2026-08-18 | 2026-10-22 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
Showing 20 of 1251. Sign in to see all of them.
Ovarian Neoplasms (1023) · Breast Neoplasms (325) · Fallopian Tube Neoplasms (268) · Carcinoma, Non-Small-Cell Lung (254) · Carcinoma, Ovarian Epithelial (249) · Endometrial Neoplasms (205) · Colorectal Neoplasms (192) · Pancreatic Neoplasms (189) · Stomach Neoplasms (170) · Neoplasms (159) · Uterine Cervical Neoplasms (144) · Prostatic Neoplasms (134) · Melanoma (133) · Triple Negative Breast Neoplasms (132) · Lung Neoplasms (131)
Female Urogenital Diseases (1251) · Female Urogenital Diseases and Pregnancy Complications (1251) · Genital Diseases (1251) · Urogenital Diseases (1251) · Genital Diseases, Female (1250) · Endocrine System Diseases (1225) · Gonadal Disorders (1224) · Ovarian Diseases (1220) · Urogenital Neoplasms (1159) · Genital Neoplasms, Female (1157) · Neoplasms by Site (1156) · Endocrine Gland Neoplasms (1142) · Neoplasms (1050) · Neoplasms by Histologic Type (603)
Carboplatin (137) · Paclitaxel (127) · pembrolizumab (69) · Cyclophosphamide (63) · Bevacizumab (52) · Cisplatin (42) · liposomal doxorubicin (41) · Gemcitabine (40) · Topotecan (34) · Nivolumab (32) · Taxes (32) · olaparib (30) · fludarabine (28) · Docetaxel (23) · Filgrastim (22)
National Cancer Institute (NCI) (75) · M.D. Anderson Cancer Center (28) · Memorial Sloan Kettering Cancer Center (21) · AstraZeneca (19) · Pfizer (18) · Gynecologic Oncology Group (14) · AbbVie (13) · Roswell Park Cancer Institute (12) · City of Hope Medical Center (11) · Eli Lilly and Company (11) · Ludwig Institute for Cancer Research (10) · Masonic Cancer Center, University of Minnesota (10) · Dana-Farber Cancer Institute (9) · Incyte Corporation (9) · University of Washington (9)
United States (857) · China (132) · Spain (106) · United Kingdom (95) · Australia (89) · Canada (89) · France (69) · Belgium (61) · Japan (47) · South Korea (47) · Netherlands (46) · Germany (43) · Italy (43) · Switzerland (26) · Denmark (23)
Paul Sabbatini, MD (7) · Kunle Odunsi (6) · Revolution Medicines, Inc. (4)
PMID 16394300, PMID 37185961, PMID 40132910, PMID 19553641, PMID 19949018, PMID 22002018, PMID 23810467, PMID 23810788, PMID 25218906, PMID 29995186, PMID 32379297, PMID 33407794, PMID 34904813, PMID 35537408, PMID 36459691, PMID 36608308, PMID 37496366, PMID 38885312, PMID 40443562, PMID 41044356, PMID 10582785, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11181662, PMID 11309294, PMID 11331762, PMID 11410496, PMID 11459964, PMID 11533692, PMID 11705489, PMID 12082455, PMID 12082456, PMID 12114401, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 12528778, PMID 12957454, PMID 14701743, PMID 14751144, PMID 14767498, PMID 15010069, PMID 15033677, PMID 15131031, PMID 15327776, PMID 15367671, PMID 15592836, PMID 15665856
2023 (17), 2018 (12), U10CA027469 (12), 2016 (9), 2017 (9), 2025 (8), UM1CA186709 (8), P30CA016056 (7), P30CA033572 (7), 2014 (6), 2015 (6), 2019 (6), U10CA180868 (6), 2009 (4), P30CA015083 (4)